Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
371 Leser
Artikel bewerten:
(2)

Orion Oyj: Change in Orion Group Executive Management Board as of February 1st, 2024 - Julia Macharey appointed Senior Vice President, People & Culture

ORION CORPORATION
STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS
22 August 2023 at 14.00 EEST

Change in Orion Group Executive Management Board as of February 1st, 2024 - Julia Macharey appointed Senior Vice President, People & Culture

Ms. Julia Macharey has been appointed Senior Vice President of Orion Group's new People & Culture group-level function and member of the Executive Management Board of Orion Group as of February 1st 2024. She will report to President & CEO Liisa Hurme. She currently holds the position of Senior Vice President, Human Resources and Operational Development at Valmet and is a member of the Valmet Executive Team. Julia Macharey holds a Master of Science degree in Economics and a Bachelor of Arts degree.

"With this appointment, I wanted to support the implementation of our global growth strategy and to strengthen the building of Orion's corporate culture. Based on her previous experience and track record, Julia Macharey will bring both global organizational and business perspective to Orion," says Orion's President & CEO Liisa Hurme.

"I am very excited about the opportunity of joining a team of world-class experts who endeavor to improve well-being through life-saving and life-improving medicines and treatments. Orion's people-oriented culture based on working together to create high-quality products is only one of the many reasons why I am looking forward to supporting Orion on its growth path," says Julia Macharey about the appointment.

The new People & Culture function will focus on developing Orion's professionals, capabilities and company culture and supporting growth, and Human Resources will be at the heart of this new group-level function as of February 1st.

"Orion's organisation has seen significant geographical expansion in recent years, and we want to continue developing our people and culture in a global and systematic way. I am excited about the new opportunities in this and I warmly welcome Julia to Orion and to our management team," says Liisa Hurme.

ANNEX: CV of Julia Macharey

Julia Macharey
Born 1977
Finnish citizen


Education:

Master of Science in Economics, University of Jyväskylä, 2000
Bachelor of Arts (Intercultural Communication), University of Jyväskylä, 1999

Career:

Valmet

2019- Senior Vice President, Human Resources and Operational Development
2014-2019 Senior Vice President, Human Resources

Metso Corporation, Metso Paper
2012-2013 Senior Vice President, Human Resources of Metso Pulp, Paper and Power segment

Pöyry Plc
2007-2012 Vice President, Human Resources of Industry Business Group


Nokia Corporation
2006-2007 Senior Manager, Business HR of Manufacturing Solutions
2004-2006 Senior Manager, Business HR of Sourcing and Procurement

SCA Hygiene Products Ltd and GmbH
2000-2004 Human Resources Manager and various HR management responsibilities

Attachment:

  • Julia Macharey (https://www.globenewswire.com/NewsRoom/AttachmentNg/2bb1fdd3-1ead-4a2c-8576-00f275e80543) (image)

Orion Corporation

Liisa Hurme

President and CEO
Olli Huotari

SVP, Corporate Functions


Contact person:
Liisa Hurme, President and CEO
tel. +358 50 966 2874, liisa.hurme@orion.fi

Contact personforthe media:
Terhi Ormio, VP, Communications
tel. + 358 50 966 4646, terhi.ormio@orion.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Attachment

  • Julia Macharey (https://ml-eu.globenewswire.com/Resource/Download/2bb1fdd3-1ead-4a2c-8576-00f275e80543)

© 2023 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.